9.33
-0.35 (-3.62%)
| Previous Close | 9.68 |
| Open | 9.74 |
| Volume | 1,809,961 |
| Avg. Volume (3M) | 2,487,164 |
| Market Cap | 1,087,794,048 |
| Price / Earnings (Forward) | 23.42 |
| Price / Sales | 0.440 |
| Price / Book | 1.15 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | -2.41% |
| Operating Margin (TTM) | -0.09% |
| Diluted EPS (TTM) | -0.810 |
| Quarterly Revenue Growth (YOY) | 16.30% |
| Total Debt/Equity (MRQ) | 59.90% |
| Current Ratio (MRQ) | 0.850 |
| Operating Cash Flow (TTM) | 18.77 M |
| Levered Free Cash Flow (TTM) | -41.00 M |
| Return on Assets (TTM) | 0.06% |
| Return on Equity (TTM) | -5.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Mixed |
| Health Information Services (Global) | Bearish | Mixed | |
| Stock | Evolent Health, Inc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 1.24% |
| % Held by Institutions | 105.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eventide Asset Management, Llc | 31 Dec 2024 | 4,552,306 |
| Ra Capital Management, L.P. | 31 Dec 2024 | 3,577,197 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (Piper Sandler, 71.49%) | Buy |
| Median | 13.50 (44.70%) | |
| Low | 12.00 (JP Morgan, 28.62%) | Buy |
| 12.00 (Citizens Capital Markets, 28.62%) | Buy | |
| Average | 13.67 (46.52%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 9.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 28 Apr 2025 | 13.00 (39.34%) | Buy | 9.34 |
| 14 Feb 2025 | 12.00 (28.62%) | Buy | 10.02 | |
| Truist Securities | 10 Apr 2025 | 14.00 (50.05%) | Buy | 9.89 |
| JP Morgan | 10 Mar 2025 | 12.00 (28.62%) | Buy | 9.10 |
| Citizens Capital Markets | 24 Feb 2025 | 12.00 (28.62%) | Buy | 10.18 |
| Needham | 21 Feb 2025 | 15.00 (60.77%) | Buy | 10.43 |
| 12 Feb 2025 | 15.00 (60.77%) | Buy | 9.60 | |
| Piper Sandler | 21 Feb 2025 | 16.00 (71.49%) | Buy | 10.43 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Apr 2025 | Announcement | Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors |
| 15 Apr 2025 | Announcement | Evolent program achieves 20% reduction in use of low-value oncology regimens |
| 10 Apr 2025 | Announcement | Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025 |
| 10 Apr 2025 | Announcement | Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025 |
| 11 Mar 2025 | Announcement | Define Ventures Appoints Carolyn Magill as Venture Partner |
| 20 Feb 2025 | Announcement | Evolent Announces Fourth Quarter and Full Year 2024 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |